InsiderTrades.com logo
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
From Traders Agency   |   Ad
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Click here now for the full details of this stock that’s set to rocket in the AI revolution…
Jeannette Potts net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Jeannette Potts Biography and Net Worth

Insider of Forma Therapeutics
Jeannette joined Forma in September 2019 with over 20 years of broad and in-depth legal experience in the biopharmaceutical industry. She is responsible for managing corporate governance and all legal matters related to Forma’s business. Prior to joining Forma, she served most recently as vice president, head counsel, research & development at Takeda Pharmaceuticals, where she was responsible for legal support and strategic guidance to Takeda’s global R&D organization (outside of Japan) in drug discovery, product development and related corporate and business development initiatives. Earlier in her career, Jeannette was an associate general counsel at Millennium Pharmaceuticals, Inc., where she held legal roles of increasing responsibility in business development, product development, commercial and compliance. Jeannette earned a Bachelor of Arts in biology from Smith College, a Ph.D. in anatomy and cell biology from the University of Virginia and a J.D. cum laude from Suffolk University.

How old is Jeannette Potts?

Dr. Potts is currently 60 years old. There are 5 older executives and no younger executives at Forma Therapeutics. The oldest executive at Forma Therapeutics is Dr. David N. Cook Ph.D., Sr. VP & Chief Scientific Officer, who is 64 years old. Learn More on Jeannette Potts' age.

How do I contact Jeannette Potts?

The corporate mailing address for Dr. Potts and other Forma Therapeutics executives is 500 ARSENAL STREET SUITE 100, WATERTOWN MA, 02472. Forma Therapeutics can also be reached via phone at 617-679-1970 and via email at [email protected]. Learn More on Jeannette Potts' contact information.

Has Jeannette Potts been buying or selling shares of Forma Therapeutics?

Jeannette Potts has not been actively trading shares of Forma Therapeutics over the course of the past ninety days. Most recently, Jeannette Potts sold 4,672 shares of the business's stock in a transaction on Wednesday, February 23rd. The shares were sold at an average price of $9.78, for a transaction totalling $45,692.16. Learn More on Jeannette Potts' trading history.

Who are Forma Therapeutics' active insiders?

Forma Therapeutics' insider roster includes Patrick Kelly (SVP), Frank Lee (CEO), Jeannette Potts (Insider), and Todd Shegog (CFO). Learn More on Forma Therapeutics' active insiders.

Jeannette Potts Insider Trading History at Forma Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/23/2022Sell4,672$9.78$45,692.16View SEC Filing Icon  
See Full Table

Jeannette Potts Buying and Selling Activity at Forma Therapeutics

This chart shows Jeannette Potts's buying and selling at Forma Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Forma Therapeutics Company Overview

Forma Therapeutics logo
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.
Read More

Today's Range

Now: $20.01
Low: $20.01
High: $20.01

50 Day Range

MA: $20.00
Low: $19.91
High: $20.01

2 Week Range

Now: $20.01
Low: $4.95
High: $20.68

Volume

1 shs

Average Volume

847,595 shs

Market Capitalization

$957.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
From Traders Agency   |   Ad
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Click here now for the full details of this stock that’s set to rocket in the AI revolution…